Leuprolide

The New England journal of medicine · 2026

Researchers found that combining enzalutamide with leuprolide led to significantly longer periods without metastasis in patients with high-risk recurrent prostate cancer compared to leuprolide alone. However, enzalutamide on its own did not show a significant survival advantage over leuprolide alone. The study highlights the potential benefits of combination therapy in improving outcomes for these patients.

• The combination of enzalutamide and leuprolide improved metastasis-free survival compared to leuprolide alone.
• The 8-year overall survival rate was 78.9% for the combination group versus 69.5% for the leuprolide-alone group.
• Enzalutamide monotherapy did not significantly improve overall survival compared to leuprolide alone.

The New England journal of medicine · 2023

Researchers found that in men with high-risk recurrent prostate cancer, the combination of enzalutamide and androgen-deprivation therapy significantly improved the time without disease progression compared to androgen-deprivation therapy alone. They also observed that enzalutamide alone was more effective than the standard treatment. Importantly, the safety profile of enzalutamide was consistent with previous studies, showing no negative impact on quality of life.

• Enzalutamide combined with androgen-deprivation therapy resulted in an 87.3% metastasis-free survival rate at 5 years, compared to 71.4% for androgen-deprivation therapy alone.
• Enzalutamide monotherapy also showed improved outcomes, with an 80.0% metastasis-free survival rate compared to leuprolide alone.
• The study found no new safety concerns and no significant differences in quality of life among the treatment groups.

The New England journal of medicine · 2020

Researchers studied the effectiveness of an oral medication called relugolix compared to the standard injectable treatment leuprolide for men with advanced prostate cancer. They found that relugolix provided faster and more sustained testosterone suppression and had a lower risk of serious cardiovascular events.

• 96.7% of men taking relugolix maintained low testosterone levels after 48 weeks, compared to 88.8% of those on leuprolide.
• Relugolix showed a significant advantage in achieving low testosterone levels quickly, with 56% of patients reaching these levels by day 4, while none on leuprolide did.
• The risk of major cardiovascular events was 54% lower in the relugolix group compared to the leuprolide group.

Prostate international · 2020

Researchers reviewed clinical studies on leuprorelin, a treatment for prostate cancer, specifically focusing on its use in Asian males. They found that leuprorelin was well tolerated and effective in lowering testosterone and prostate-specific antigen levels, while also improving patients' quality of life.

• Leuprorelin was effective in reducing testosterone and prostate-specific antigen levels in Asian males with prostate cancer.
• The treatment was well tolerated, with common side effects including hot flushes and mild liver issues.
• Patients receiving leuprorelin experienced improved quality of life and reasonable survival rates.

Asian Pacific journal of cancer prevention : APJCP · 2019

Researchers examined the use of leuprorelin, a hormone therapy, in premenopausal women with breast cancer in Asia. They found that leuprorelin can help preserve ovarian function and reduce symptoms related to ovarian failure during chemotherapy.

• Leuprorelin was shown to preserve ovarian function in breast cancer patients undergoing chemotherapy.
• The treatment reduced symptoms of ovarian failure and the occurrence of early menopause.
• Common side effects included hot flushes, mood swings, and urogenital symptoms.

Clinical pharmacokinetics · 2002

Researchers studied leuprorelin acetate, a medication that reduces hormone production by using a special delivery method to avoid daily injections. They found that depot formulations can release the drug steadily over one to four months, maintaining effective levels in the body while being generally well tolerated.

• Depot formulations of leuprorelin provide sustained drug release, reducing the need for frequent injections.
• Researchers observed that the drug maintains steady plasma concentrations for extended periods, depending on the formulation used.
• Local reactions at the injection site were more common with longer-acting depot versions compared to shorter ones.

Drugs · 1994

Researchers reviewed the use of leuprorelin, a hormone therapy, for conditions like advanced prostate cancer, endometriosis, and precocious puberty. They found it effective in managing symptoms and improving patient outcomes, with considerations for side effects and treatment duration.

• Leuprorelin was found to be effective for men with advanced prostate cancer, showing fewer serious cardiovascular side effects compared to other treatments.
• In women with endometriosis, leuprorelin significantly improved symptoms but should only be used for a limited duration due to potential bone density loss.
• For children with precocious puberty, leuprorelin was observed to slow growth and sexual maturation, potentially increasing predicted adult height.

Journal of obstetric, gynecologic, and neonatal nursing : JOGNN · 1994

Researchers reviewed the use of gonadotropin-releasing hormone (GnRH) agonists, a new class of drugs that significantly lower testosterone and estrogen levels. These drugs are approved for conditions like advanced prostate cancer and endometriosis, and are being studied for various other health issues. The study highlights their growing importance in hormonal therapy.

• GnRH agonists include medications like leuprolide, nafarelin, and goserelin, which are used for specific medical conditions.
• These drugs are being investigated for additional uses in diseases such as uterine fibroids and breast cancer.
• The review emphasizes the potential of GnRH agonists as a significant advancement in hormonal therapy over recent decades.

Drugs & aging · 1991

Researchers reviewed leuprorelin, a medication used for prostate disorders, and found it effectively delays the progression of advanced prostate cancer in many men. The study noted that leuprorelin is generally well-tolerated compared to other treatments and can also help reduce symptoms in benign prostate enlargement.

• Researchers observed that leuprorelin delays cancer progression in 70 to 90% of men with advanced prostate cancer.
• The study found that leuprorelin is better tolerated than estrogen therapy and has fewer side effects.
• Researchers noted that leuprorelin can reduce symptoms of benign prostatic hyperplasia, although continuous treatment is necessary.